History-adjusted marginal structural models for estimating time-varying effect modification

被引:40
作者
Petersen, Maya L.
Deeks, Steven G.
Martin, Jeffrey N.
van der Laan, Mark J.
机构
[1] Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA USA
关键词
antiretroviral therapy; highly active; causality; confounding factors (epidemiology); HIV; longitudinal studies; observational data; structural model; time-dependent covariate;
D O I
10.1093/aje/kwm232
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Much of epidemiology and clinical medicine is focused on estimating the effects of treatments or interventions administered over time. In such settings of longitudinal treatment, time-dependent confounding is often an important source of bias. Marginal structural models (MSMs) are a powerful tool for estimating the causal effect of a treatment using observational data, particularly when time-dependent confounding is present. In recent statistical work, van der Laan et al. presented a generalized form of MSMs called "history-adjusted" MSMs (Int J Biostat 2005; 1:article 4). Unlike standard MSMs, history-adjusted MSMs can be used to estimate modification of treatment effects by time-varying covariates. Estimation of time-dependent causal effect modification is frequently of great practical relevance. For example, clinical researchers are often interested in how the prognostic significance of a biomarker for treatment response can change overtime. This article provides a practical introduction to the implementation and interpretation of history-adjusted MSMs. The method is illustrated using a clinical question drawn from the treatment of human immunodeficiency virus infection. Observational cohort data from San Francisco, California, collected between 2000 and 2004, are used to estimate the effect of time until switching antiretroviral therapy regimens among patients receiving a nonsuppressive regimen and how this effect differs depending on CD4-positive T-lymphocyte count.
引用
收藏
页码:985 / 993
页数:9
相关论文
共 15 条
[1]   Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia [J].
Deeks, SG ;
Barbour, JD ;
Grant, RM ;
Martin, JN .
AIDS, 2002, 16 (02) :201-207
[2]   Treatment of anti retroviral-drug-resistant HIV-1 infection [J].
Deeks, SG .
LANCET, 2003, 362 (9400) :2002-2011
[3]   Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection [J].
Deeks, SG ;
Barbour, JD ;
Martin, JN ;
Swanson, MS ;
Grant, RM .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) :946-953
[4]   Administration of parenteral iron and mortality among hemodialysis patients [J].
Feldman, HI ;
Joffe, M ;
Robinson, B ;
Knauss, J ;
Cizman, B ;
Guo, WS ;
Franklin-Becker, E ;
Faich, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (06) :1623-1632
[5]  
Joffe M, 2004, AM J EPIDEMIOL, V159, pS66
[6]  
Joffe M, 2001, AM J EPIDEMIOL, V153, pS261
[7]   Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen [J].
Piketty, C ;
Weiss, L ;
Thomas, F ;
Mohamed, AS ;
Belec, L ;
Kazatchkine, MD .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (09) :1328-1335
[8]  
Robins J. M., 2000, 1999 P AM STAT ASS A, P6
[9]   Marginal structural models and causal inference in epidemiology [J].
Robins, JM ;
Hernán, MA ;
Brumback, B .
EPIDEMIOLOGY, 2000, 11 (05) :550-560
[10]  
Robins JM., 1998, Encyclopedia of Biostatistics, P4372, DOI DOI 10.1002/0470011815.B2A11071